GT Biopharma Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products in the United States. The company is engaged in discovering, developing, and commercializing therapeutics from its proprietary product platform across various disease areas, mainly focused on the treatment of cancer. Its TriKE (Tri-specific Killer Engager) platform offers immuno-oncology products designed to treat hematologic malignancies, sarcoma, and solid tumors.
Last trade$3.30
Day change-$0.24 (-6.79%)
Day range$3.30 – $4.30
Volume61,834
Market cap$6M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$6.39M
Price / earnings
—
Price / book
1.79×
Price / sales
—
EV / sales
—
EV / EBITDA
-0.09×
Profitability
Earnings per share
-$18.16
Return on assets
-566.02%
Return on equity
-917.93%
Dividend yield
3.59%
Liquidity and leverage
Debt / equity
0×
Current ratio
2.61×
Quick ratio
2.61×
Cash ratio
2.24×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$14.43M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for GTBP, quarterly periods
Line item
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Q3 FY2024 Sep 30, 2024
Revenue
$0
$0
$0
$0
$0
$0
$0
$0
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$0
$0
$0
$0
$0
$0
$0
$0
Selling, general and administrative
$3.46M
$2.44M
$4.22M
$2.75M
$1.15M
$833K
$1.83M
$2.3M
Research and development
$1.06M
$413K
$1.38M
$634K
$363K
$1.1M
$1.93M
$1.31M
Total operating expenses
$4.51M
$2.85M
$5.6M
$3.38M
$1.51M
$1.93M
$3.76M
$3.6M
Operating income
-$4.51M
-$2.85M
-$5.6M
-$3.38M
-$1.51M
-$1.93M
-$3.76M
-$3.6M
Interest expense
-$64K
-$63K
-$127K
$0
$0
$0
$0
$0
Income before taxes
-$4.52M
-$2.83M
-$23.03M
$8.3M
-$30.17M
-$776K
-$3.78M
-$3.41M
Income taxes
$0
$0
$0
$0
$0
$0
$0
$0
Net income
-$4.52M
-$2.83M
-$23.03M
$8.3M
-$30.17M
-$776K
-$3.78M
-$3.41M
Net income attributable to common shareholders
-$4.59M
-$3.37M
-$28.9M
$4.1M
-$30.25M
-$776K
-$3.78M
-$3.41M
EBITDA
-$4.51M
-$2.85M
-$5.6M
-$3.38M
-$1.51M
-$1.93M
-$3.76M
-$3.6M
Basic earnings per share
-$3.00
-$2.75
-$62.44
$26.00
-$273.00
-$8.25
-$41.71
-$38.25
Diluted earnings per share
-$3.00
-$2.75
-$62.44
$26.00
-$273.00
-$8.25
-$41.71
-$38.25
Recent news
Company coverage with links to the original publishers.
GT Biopharma announced its third cancer drug, GTB-5550, entered Phase 1 clinical trials on May 14, 2026, marking the company's first expansion into solid tumors. Despite having three drugs in human trials—unusual for a micro-cap—the company trades at a significant valuation discount compared to peers, with only ~$9 million in cash and a runway into late 2026. The gap between its scientific promise and market valuation presents both opportunity and substantial risk, with near-term catalysts including clinical data updates and financing announcements expected in H2 2026.
A new generation of immuno-oncology therapies targeting historically immunotherapy-resistant solid tumors like prostate and pancreatic cancer is advancing rapidly through clinical trials in 2026. Four distinct mechanistic approaches—including NK cell engagers, oncolytic virus immune-primers, and tumor microenvironment-conditional antibodies—are being developed by multiple biotech companies, with over $1.7 billion in dealmaking activity. GT Biopharma's GTB-5550 NK cell engager and Vir Biotechnology's VIR-5500 PSMA-targeted T-cell engager represent leading programs in this emerging therapeutic landscape.
The market is shifting focus towards technologies that can detect previously invisible threats across healthcare, resource exploration, and diagnostics, with several companies developing innovative solutions for cardiac care, diabetes treatment, cancer therapy, and mineral exploration.
Multiple biotech companies are advancing innovative immunotherapy and targeted treatments for blood cancers, with significant clinical trial progress and FDA approvals in acute myeloid leukemia (AML) and related hematologic conditions.
GT Biopharma reported progress on its Phase 1 clinical trial for GTB-3650, a TriKE® therapy targeting CD33-expressing hematologic malignancies, with successful advancement to Cohort 4 and no observed safety issues. The company plans to provide a trial update in Q1 2026 and anticipates submitting an IND for GTB-5550 in late December 2025.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.